touchREVIEWS in RMD – Volume 4, Issue 1 – 2025

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

International experts from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have recently partnered to produce the much-anticipated classification criteria for antiphospholipid syndrome (APS), which were published in Arthritis & Rheumatology in August 2023.1 Prior to the publication of the new ACR/EULAR APS classification criteria, research studies used the Sapporo criteria, […]

Rheumatoid arthritis (RA) is one of the most challenging autoimmune diseases. Early, targeted and effective therapy is crucial for achieving remission and preventing long-term joint destruction. Over the past two decades, tumour necrosis factor (TNF) inhibitors (TNFi) have been the mainstay of first-line biotherapy, delivering transformative outcomes for many patients. However, despite their efficacy, their […]

Chronic back pain (CBP), defined as back pain lasting for 3 months or more, is the most common pain condition globally.1 Greater healthcare utilization, productivity limitations and poor quality of life have immediate and long-term impacts on patients and the healthcare system.2 The guidelines recommend physiotherapy as a frontline intervention, alongside education and behavioural interventions.3 […]

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Hypermobility spectrum disorders (HSDs) refer to a group of conditions characterized by an increased range of motion in joints beyond the normal limits, often due to connective tissue laxity. More stringent criteria are applied in the diagnosis of hypermobile Ehlers–Danlos syndrome (hEDS).1 HSDs are increasingly well-recognized among young people and frequently attract referrals to healthcare providers […]